Treatment Attrition, Concomitant Pharmaceutical Use, Temporal Claims-Based Utilization, and Real-World Characteristics Among Esketamine New Initiators in the United States, 2019-2022
medRxiv – April 23, 2024
Source: medRxiv/bioRxiv/arXiv
Summary
Did you know that treatment dropout rates can significantly impact mental health care? This study explored the experiences of individuals starting esketamine therapy in the U.S. from 2019 to 2022. It found that while many faced challenges like high costs and additional medications, overall outcomes showed promise, highlighting the need for tailored support in mental health treatment.
Abstract
Aims To investigate real-world treatment attrition, concomitant use of pharmaceuticals with known drug-interactions, total cost of care, claims-based outcomes, and health disparities for individuals initiated on esketamine therapy in the United States.